Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia - Join Clinical Trial NCTNCT06253663
How to Join This Clinical Trial - NCTNCT06253663
Learn how to participate in this PHASE2 trial studying an investigational therapy for Lymphoma, Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Lymphoid, Lymphoma, Mantle-Cell. Current status: ACTIVE_NOT_RECRUITING.
Am I Eligible for This Clinical Trial?
This clinical research study is looking for participants with Lymphoma, Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Lymphoid, Lymphoma, Mantle-Cell. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.
- Condition Being Studied
- Lymphoma, Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Lymphoid, Lymphoma, Mantle-Cell
- Treatment Being Tested
- Investigational treatment
- Study Phase
- PHASE2 - Safety and effectiveness study
- Enrollment Status
- ACTIVE_NOT_RECRUITING
- Study Identifier
- NCTNCT06253663 - ClinicalTrials.gov Identifier
- Sponsored By
- Study sponsor
What to Expect as a Participant
Participating in this clinical trial involves:
- Initial screening to determine eligibility
- Regular study visits and health assessments
- Receiving the study treatment or placebo
- Medical monitoring and follow-up care
- Contributing to medical research that may help others
- Potential access to new treatments before they're widely available
Clinical Trial Benefits and Compensation
Participants in this clinical research study may receive:
- Close medical monitoring by healthcare professionals
- Access to potential new treatments
- Compensation for time and travel (varies by study)
- No-cost study-related medical care
- The opportunity to help advance medical knowledge
Where Is This Clinical Trial Located?
This study is enrolling participants at 9 locations. Find a study site near you:
Clinical Research Site
Chiba, 260-8677 - Japan
Status: Contact for availability
Clinical Research Site
Fukuoka, 812-8582 - Japan
Status: Contact for availability
Clinical Research Site
Hokkaido, 060-8648, - Japan
Status: Contact for availability
Clinical Research Site
Kyoto, 606-8507 - Japan
Status: Contact for availability
Clinical Research Site
Miyagi, 980-8574 - Japan
Status: Contact for availability
Clinical Research Site
Okayama, 700-8558 - Japan
Status: Contact for availability
Clinical Research Site
Tokyo, 104-0045 - Japan
Status: Contact for availability
Clinical Research Site
Tokyo, 113-8431 - Japan
Status: Contact for availability
Clinical Research Site
Tokyo, 113-8677 - Japan
Status: Contact for availability
How to Enroll in This Study
To learn more about participating in this PHASE2 clinical trial for Lymphoma, Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Lymphoid, Lymphoma, Mantle-Cell:
- Review the eligibility criteria with your healthcare provider
- Contact the study team for a pre-screening interview
- Schedule an in-person screening visit if eligible
- Review and sign the informed consent form
- Begin participation in the clinical trial
Why Choose Quri.ai Study Finder
Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:
- Discover clinical trials before competitors
- Access exclusive contact information
- Track sponsor pipelines and opportunities
- Connect with decision makers directly
- Win more business partnerships